Are you ready for a glimpse into the regenerative medicine frontier? Join the captivating webinar, "Stem Cell Therapy in OA: Making It Possible in Practice," presented by Russell Chandler, BVSc Cert SAO MSc (Ortho Eng) MRCVS. Brought to you by TVM, this webinar promises an engaging exploration of the revolutionary world of stem cell therapy.

Understanding the Magic: A Deep Dive into Stem Cell Therapy

Russell Chandler kicks off with a crystal-clear breakdown of stem cell therapy, focusing on mesenchymal cells (MSCs) and their transformative potential. With vivid illustrations, he unravels the immunotypes and paracrine mechanisms, paving the way for a discussion on therapeutic mechanisms—immunomodulatory, anti-inflammatory, and pro-angiogenic. Get ready for a theoretical journey beautifully illustrated for clarity.

Navigating the Practical Realms of Stem Cell Therapy

Delving into the practical aspects, Russell sheds light on stem cell sources, tissue origins, and animal varieties. From bone marrow to adipose tissue, he covers it all. Ever wondered about autologous, allogenic, or xenogeneic sources? Russell demystifies the terms, making stem cell therapy more accessible. The process involves collecting adipose tissue, sending it to a lab for isolation, and eventually injecting it into a joint. A step-by-step guide ensures clarity on the procedure.

Identifying the Ideal Candidates for Stem Cell Therapy

The big question: Which patients are ideal for stem cell therapy? Russell lays out the criteria: dogs with osteoarthritis, preferably younger, less severe, and less chronically affected. Detailed insights into the results of stem cell therapy in both young and old dogs follow, showcasing promising outcomes. With an 81% improvement in the quality of life for older dogs and even better responses in the younger ones, it's clear that stem cell therapy is a game-changer for osteoarthritis.

Championing a Paradigm Shift in Standard Care

Is stem cell therapy poised to become the new standard of care? Russell argues convincingly for its inclusion, highlighting the current lack of disease-modifying therapies. However, caution is advised in specific situations, such as cases involving cancer, unconfirmed diagnosis, or severe systemic diseases. With thought-provoking insights, Russell guides the audience through a paradigm shift in osteoarthritis management.

Stem Cells in Action: Clinical Trials Unveiled

Clinical trials are the backbone of validating any groundbreaking therapy. Russell delves into two double-blind, placebo-controlled trials involving stem cell therapy for hip and elbow arthritis. Results indicate safety, efficacy, ease of administration, and long-lasting effects. Practical slides demonstrate the simplicity of injecting stem cells into joints, emphasizing minimal postoperative complications.

A Prodigy Emerges: DogStem - A Licensed Breakthrough

The webinar takes an exciting turn as Helen Harrison, BVSc CertAVP MRCVS, introduces DogStemr, the first licensed stem therapy for canine osteoarthritis, courtesy of TVM. With 7.5 million stem cells in a 1 ml ready-to-use formulation, DogStem offers proven efficacy, reducing pain and lameness while enhancing mobility and quality of life. Helen unveils the product's local action, lack of systemic contraindications, and ethical, non-invasive stem cell sourcing. Clinical trials showcase outstanding results for up to 12 months post a single intra-articular injection.

Seizing the Future: DogStem's Journey from Trials to Practice

As the webinar concludes, Helen provides valuable insights into the clinical trials, including impressive long-term outcomes ranging from 12 to 18 months. DogStem emerges as a beacon of hope, offering an efficient, ethical, and non-invasive solution to canine osteoarthritis. With seamless delivery to practices and an extended shelf life, DogStem promises to redefine osteoarthritis management.

Embark on this riveting journey into the future of veterinary medicine with stem cell therapy. Tune in to the webinar, embrace the transformative potential, and witness the birth of a new era in regenerative medicine.

Note: The webinar was generously sponsored by TVM, making this enlightening exploration possible.